Omada Health (NASDAQ:OMDA) CFO Steven Cook Sells 15,235 Shares

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 15,235 shares of Omada Health stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $25.03, for a total transaction of $381,332.05. Following the completion of the transaction, the chief financial officer owned 187,209 shares of the company’s stock, valued at $4,685,841.27. This trade represents a 7.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Omada Health Stock Down 0.7%

Omada Health stock opened at $23.84 on Thursday. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92. The company’s 50 day moving average is $20.74 and its two-hundred day moving average is $16.38. The firm has a market cap of $1.46 billion, a PE ratio of 476.80 and a beta of 1.73.

Omada Health (NASDAQ:OMDA) last posted its earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.10. Omada Health had a return on equity of 2.67% and a net margin of 1.39%.The firm had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. On average, equities research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on OMDA shares. BTIG Research upped their price target on Omada Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday. The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Wells Fargo & Company upped their price objective on Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Weiss Ratings upgraded Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, Barclays upped their price target on shares of Omada Health from $20.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new stake in shares of Omada Health in the 4th quarter worth about $29,000. TD Waterhouse Canada Inc. purchased a new position in Omada Health during the 4th quarter valued at about $32,000. Raymond James Financial Inc. acquired a new position in Omada Health during the second quarter worth about $32,000. Inlight Wealth Management LLC purchased a new stake in shares of Omada Health in the fourth quarter valued at about $45,000. Finally, Versant Capital Management Inc lifted its holdings in shares of Omada Health by 319.3% in the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after purchasing an additional 2,283 shares in the last quarter.

Key Stories Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q2 results showed improving profitability and growth. Omada reported earnings of $0.08 per share versus the consensus estimate of a $0.02 loss, while revenue of approximately $87.8 million exceeded expectations of $80.9 million. The results suggest that the company’s digital chronic-care business is converting revenue growth into earnings. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Analyst price targets continue to rise. Robert W. Baird lifted its target from $15 to $25 while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG, contributing to a consensus “Moderate Buy” rating and an average target of $25.67.
• Neutral Sentiment: Baird’s neutral rating signals valuation concerns. Although the higher target implies additional upside, the firm’s hold-equivalent rating suggests that much of Omada’s improved earnings outlook may already be reflected in the stock’s valuation.
• Negative Sentiment: Multiple senior executives sold shares. CEO Sean Duffy sold a combined 21,570 shares, CFO Steven Cook sold 16,842 shares, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. The transactions totaled roughly $1.16 million and occurred at prices near $25. While insider sales may reflect personal or equity-compensation planning, the concentration of selling can weigh on sentiment because it reduces management ownership.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.